Biopharmaceutical Developments--An Emerging Technology Analysis

Table of Contents

• 1. Executive Summary
  • 1. Introduction
    • 1. Introduction to Biopharmaceuticals
    • 2. Overview of the Biopharmaceutical Industry
  • 2. Scope & Methodology
    • 1. Scope and Segmentation of this Research Service
    • 2. Methodology
• 2. Monoclonal Antibody Technologies
  • 1. Technology Primer
    • 1. An Overview of Monoclonal Antibodies
    • 2. Applications
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Cost-Effective System for Production of Monoclonal Antibodies in Yeast
    • 2. Antibody-Vaccine Combination Therapy for Melanoma
    • 3. Abbotts Fully Human Anti-Il-12 Monoclonal Antibody
    • 4. Monoclonal Antibody for Autoimmune Diseases
    • 5. Anti-IL-9 Monoclonal Antibody for Controlling Asthma
  • 3. Influential Market Factors
    • 1. Industry Trends
    • 2. A Brief on Important Clinical Trials
• 3. Vaccines and Antigens
  • 1. Technology Primer
    • 1. An Overview of Vaccines
    • 2. Emerging Applications of Vaccines
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. DNA Sequences for Stimulating Immune Responses
    • 2. Single-Dose AIDS Vaccine in Phase I Trials
    • 3. Prostate Cancer Vaccine in Phase III Trials
    • 4. Novel Cancer Immunotherapy Product for Colorectal Cancer
  • 3. Influential Market Factors
    • 1. Industry Trends
    • 2. A Brief on Important Clinical Trials
• 4. Tissue Engineering
  • 1. Technology Primer
    • 1. Overview
    • 2. Applications
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Stem Cell Therapy for Regeneration of Meniscus
    • 2. Advances in Cloning Create Patient-Specific Stem Cells
    • 3. Feeder-Free Derivation of Embryonic Stem Cells
    • 4. Naturally-Derived Extracellular Matrix Material for Wound Management
    • 5. Telomerase Technology for Developing Human Embryonic Stem Cells
  • 3. Influential Market Factors
    • 1. Industry Trends
    • 2. A Brief on Important Clinical Trials
• 5. Hormones and Enzymes
  • 1. Technology Primer
    • 1. Human Insulins
    • 2. Human Growth Hormones
    • 3. Tissue Plasminogen Activators
    • 4. Thyroid Stimulating Hormones
    • 5. Fertility Hormones
    • 6. Blood Clotting Factors
    • 7. Recombinant Enzymes
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Recombinant Enzyme for Dissolving Blood Clots
    • 2. Enzyme Replacement Therapy for Mucopolysaccharidosis
    • 3. Natural Plant Enzyme to be a Potential Candidate for Lung Cancer
    • 4. Recombinant Human Thrombin as an Alternative to Bovine-Derived Product
• 6. Cytokines and Peptide Therapeutics
  • 1. Technology Primer
    • 1. Colony Stimulating Factors
    • 2. Interleukins
    • 3. Interferons
  • 2. Noteworthy Innovations at Key Companies; Academic and Government-Related Institutions
    • 1. Low Dose Interferon Alpha Provides Effective Treatment for Variety of Conditions
    • 2. Natural Peptide Promotes Wound Healing
    • 3. Discovery of Protein Leads to Potential Pathway for Treating MultiplemSclerosis
    • 4. Recombinant Natriuretic Peptide for Heart Failure
    • 5. Protein as a Marker and Target for Breast Cancer
    • 6. Recombinant Beta Interferon for Multiple Sclerosis
• 7. Technology Adoption Factor Analysis and Commercial Landscape
  • 1. Technology Analysis
    • 1. Technology Accelerators
    • 2. Technology Roadblocks
    • 3. Regulatory Trends
  • 2. Corporate Collaborations
    • 1. Part I
    • 2. Part II
• 8. Database of Key Industry Participants; Selected Patents & Glossary
  • 1. Database of Key Industry Participants
    • 1. Companies and Organizations
    • 2. Universities and Academia
  • 2. Selected Patents & Glossary
    • 1. Important Patents I
    • 2. Important Patents II
• 9. Critical Reference Tables
  • 1. Healthcare Expenditure
    • 1. Government Healthcare Expenditure
    • 2. Private Healthcare Expenditure
  • 2. Biotech Expenditure
    • 1. Number of Biotech Companies (1999-2006)
    • 2. Government Investment in Biotech R&D (1999-2006)
    • 3. Private Investment in Biotech R&D (1999-2006)
  • 3. Number of Biotech Patents
    • 1. USPTO Biotech Patents (1996-2000)
    • 2. EPO Biotech Patents (1996-2000)